Ocular Therapeutix's Intravitreal Implant Shows Decrease In Retinal Fluid In Early-Stage Wet AMD Study

  • Ocular Therapeutix Inc (NASDAQ: OCUL) on Friday released limited data from its presentation on the ongoing Phase 1 trial evaluating OTX-TKI for wet age-related macular degeneration and other retinal diseases. 
  • Ocular presented the data at the Angiogenesis, Exudations, and Degeneration 2021 Meeting.
  • OTX-TKI is an axitinib intravitreal implant for the treatment of wet age-related macular degeneration (AMD).
  • Interim data showed that some subjects showed a decrease in the intraretinal or subretinal fluid by two months in Cohorts 2 (400 µg) & 3a (600 µg). While the combination of OTX-TKI and Anti-VEGF in Cohort 3b showed a decrease immediately, as early as a week after treatment in two subjects.
  • Some subjects demonstrated the durability of therapy for up to 10 months, and one subject demonstrated durability to 13.5 months in cohort 2 (400 µg).
  • One subject in cohort 3a (600 µg) demonstrated the durability of therapy for up to 6 months.
  • The implant was biodegraded in all subjects in Cohort 1 by 9-10.5 months.
  • OTX-TKI was generally well tolerated, with a favorable safety profile, and no ocular serious adverse events were observed. 
  • Take a look at the presentation here.
  • Price Action: OCUL closed 1.92% down at $19.38 on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CareSmall CapGeneralAge-Related Macular Degeneration
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!